Zoono Group Limited (ZNO) AI Stock Analysis

• Market Cap: AU$12.09M
• Dividend Yield: N/A
• Average Volume (3M): 125.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -48.53%
• EPS Growth: 55.02%
• Country: AU
• Employees: 2
• Sector: Consumer Defensive
• Sector Strength: 57
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 377,862,550
• 10 Day Avg. Volume: 184,728
• 30 Day Avg. Volume: 125,490
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

The overall stock score for Zoono Group Limited is 40, reflecting significant financial challenges with declining revenues, negative profitability, and cash flow issues. While the stock shows some positive technical momentum, the lack of profitability and valuation concerns, due to a negative P/E ratio and absence of a dividend yield, weigh heavily on the overall assessment. The technical analysis offers some hope, but financial and valuation weaknesses are predominant factors affecting the score.

Zoono Group Limited Business Overview & Revenue Model

Company Description

Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products in New Zealand and internationally. The company's products include hand sanitizers, textile applicators, mould remediation, and surface sanitizers. It serves airlines, healthcare, childcare, facilities management, transportation, education, and hospitality sectors. The company was incorporated in 1986 and is headquartered in Auckland, New Zealand.

How the Company Makes Money

Zoono Group Limited primarily generates revenue through the sale of its antimicrobial products to various markets, including healthcare, hospitality, transportation, and consumer sectors. The company's revenue streams include direct sales to businesses and consumers, as well as partnerships and distribution agreements with third-party companies that extend its market reach. Zoono's earnings are bolstered by its ability to secure significant contracts and partnerships with organizations seeking effective antimicrobial solutions. Additionally, the company invests in research and development to enhance its product offerings and adapt to emerging market needs, which can contribute to increased sales and market presence.

Zoono Group Limited Financial Statement Overview

Summary

Zoono Group Limited is facing substantial financial difficulties, with negative margins and cash flows indicating a struggle in maintaining operational and financial health. The company is not profitable, with negative gross and net profit margins, and is experiencing declining revenues. The balance sheet shows moderate stability with positive equity but shrinking total assets. Cash flow issues are evident with negative operating and free cash flow, highlighting cash management challenges.

Income Statement

Zoono Group Limited has experienced a significant decline in its financial performance. The gross profit margin is negative due to the gross loss, and the net profit margin is also negative, indicating the company is not profitable. The revenue has drastically reduced from historical figures, suggesting a critical downturn in business operations. The absence of a positive EBIT and EBITDA further underscores operational challenges.

Balance Sheet

The balance sheet shows a moderate level of stability with a positive stockholders' equity. However, the debt-to-equity ratio is not available due to missing debt figures in prior years, making it hard to assess leverage trends. The equity ratio indicates the company is primarily financed by equity, which is a positive aspect. However, the shrinking total assets over the years can point to a declining financial condition.

Cash Flow

The cash flow situation is concerning with negative operating and free cash flow, indicating difficulties in generating cash from operations. The absence of free cash flow growth and a poor operating cash flow to net income ratio highlight cash management challenges.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	960.30K	―	―	25.22M	36.34M
Gross Profit	251.07K	―	―	11.88M	24.61M
EBITDA	―	―	―	―	18.12M
Net Income	-8.30M	―	-10.67M	―	14.61M
Balance Sheet
Total Assets	9.01M	13.40M	17.68M	29.46M	32.43M
Cash, Cash Equivalents and Short-Term Investments	1.79M	―	―	―	―
Total Debt	726.63K	―	―	―	―
Total Liabilities	2.76M	―	―	―	12.83M
Stockholders Equity	6.24M	10.16M	―	19.68M	19.59M
Cash Flow
Free Cash Flow	-3.16M	―	―	―	―
Operating Cash Flow	-2.93M	―	―	―	―
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	3.99M	―	―	―	―

Zoono Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 155.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ZNO.

Zoono Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$20.97B	14.57	-8.07%	3.14%	2.79%	-9.97%
ZNO	40 Underperform	AU$12.09M	―	-79.75%	―	-48.53%	55.02%
CCO	36 Underperform	AU$9.03M	―	-548.03%	―	192.34%	68.06%
NGS	31 Underperform	AU$3.70M	―		―	-16.29%	58.77%
SKN	30 Underperform	AU$3.15M	―		―	252.94%	81.95%
SPG	―	AU$85.88M	―	-45.49%	―	―	―
BFC	―	AU$5.99M	―		―	―	―

Zoono Group Limited Corporate Events

Zoono Group Addresses ASX Inquiry Amid Stock Price Fluctuations

Zoono Group Limited has responded to an ASX inquiry regarding a notable fluctuation in its stock price and trading volume, clarifying that it is unaware of any undisclosed information that could explain the market activity. The company attributes the interest to ongoing projects, particularly its shelf-life extension trials with OSY Group Ltd, which are progressing well in the UK and could potentially lead to broader adoption in food packaging. Zoono confirms its compliance with ASX listing rules and emphasizes its commitment to transparency with stakeholders.

Zoono Group Reports Progress in Shelf-Life Extension Technology

Zoono Group Limited has reported significant progress in its shelf-life extension technology, with successful trials conducted across 12 countries and involving a diverse range of products beyond soft fruits, such as vegetables, meat, fish, and more. The company is optimistic about future revenue streams from this niche market and anticipates increased sales revenues in the upcoming quarters, supported by ongoing trials and expected orders from Asian markets.